References
- British National Formulary, Number 51, British Medical Association, British Pharmaceutical Society, March 2006.
- Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia, Technology Appraisal Guidance No. 43, National Institute for Clinical Excellence, London, June, 2002.
- Thomson LDG. Management of schizophrenia in conditions of high security. Adv Psychiatr Treat 2000; 6: 252–60
- McGrath J, Emmerson WB. Treatment of schizophrenia. Br Med J 1999; 319: 1045–8
- Spina E, Avenoso A, Facciola G. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psyhcopharmacology 2000; 148: 83–9
- Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789–97
- Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156(7)990–9
- Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia ( Cochrane Review). In: The Cochrane Library, Issue 1. ChichesterUK: John Wiley & Sons, Ltd; 2004.
- Bell R, McLaren A, Galanos J, Copolov D. The clinical use of plasma clozapine levels. Aust NZ J Psychiatry 1998; 32: 567–74
- Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24(2)161–76
- Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997; 171: 109–12
- Khan A, Preskorn S. Examining concentration-dependent toxicity of clozapine: Role of therapeutic drug monitoring. J Psychiatr Pract 2005; 11(5)289–301
- Spina E, De Leon J. Metabolic drug interactions with newer antipsychotics: A comparative review. Basic Clin Pharmacol Toxicol 2007; 100: 4–22
- Oyewumi LK, Cernovsky ZZ, Freeman DJ, Streiner DL. Relation of blood counts during clozapine treatment to serum concentrations of clozapine and nor-clozapine. Can J Psychiatry 2002; 47: 257–61
- Llorca PM, Lancon C, Disdier B. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: Clinical response and plasma concentrations. J Psychiatry Neurosci 2002; 27(1)30–7
- Olesen OV. Therapeutic drug monitoring of clozapine concentrations. Clin Pharmacokinet 1998; 34(6)497–502
- Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 2001; 52: 45–54s
- Fabrazzo M, La Pia S, Monteleone P, Esposito G, Pinto A, De Simone L, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology 2002; 27: 1050–5
- Rostrami-Hodjegan A, Amin A, Spencer E, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharm 2004; 24(1)70–8
- Vander Zwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment refractory schizophrenia to clozapine within three serum ranges. Am J Psychiatry 1996; 153(12)1579–84
- Swinton M, McNamee H. Clozapine in forensic setting: Persuading patients. Br J Forensic Pract 2003; 5(2)33–8
- Swinton M, Ahmed AG. Reasons for non-prescription of clozapine in treatment resistant schizophrenia. Criminal Behav Ment Health 1999; 9: 207–14
- Coker-Adeyemi F, Taylor D. Clozapine Levels in patients switched from clozapine liquid to tablets. Pharm J 2002; 269: 650–2
- Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26(2)156–60
- Diaz FJ, Leon J, Josiassen R, Cooper T, Simpson G. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res 2005; 72: 131–5